CN106727620A - Application of the phosphopyridoxal pyridoxal phosphate in the medicine for preparing treatment oophoroma - Google Patents
Application of the phosphopyridoxal pyridoxal phosphate in the medicine for preparing treatment oophoroma Download PDFInfo
- Publication number
- CN106727620A CN106727620A CN201611096574.9A CN201611096574A CN106727620A CN 106727620 A CN106727620 A CN 106727620A CN 201611096574 A CN201611096574 A CN 201611096574A CN 106727620 A CN106727620 A CN 106727620A
- Authority
- CN
- China
- Prior art keywords
- pyridoxal phosphate
- phosphopyridoxal pyridoxal
- application
- medicine
- oophoroma
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The present invention relates to application of the phosphopyridoxal pyridoxal phosphate in the medicine for preparing treatment oophoroma.The present invention is experiments prove that phosphopyridoxal pyridoxal phosphate can suppress human epithelial ovarian carcinoma cells proliferation, and inhibitory action is very notable, therefore can be used to prepare the medicine for the treatment of oophoroma, or preparation research ovary carcinogenesis development mechanism related reagent.Because phosphopyridoxal pyridoxal phosphate is the activity form of vitamin B6, and vitamin B6 is water soluble vitamin, even if heavy dose of application is also comparatively safe without toxicity, therefore phosphopyridoxal pyridoxal phosphate has very strong clinical practice possible in terms of oophoroma is treated.
Description
Technical field
The present invention relates to molecular biology and pharmaceutical technology field, specifically, it is related to phosphopyridoxal pyridoxal phosphate preparing treatment
Application in the medicine of oophoroma.
Background technology
The phosphopyridoxal pyridoxal phosphate (- phosphate monohydrate of PLP, Pyridoxal 5 ') is the active shape of vitamin B6
Formula, molecular structural formula is：
PLP is the coenzyme of various enzymes, participates in more than 140 kinds of catalytic reaction, such as metabolism of homocysteine amino acid, youngster
Synthesis of neurotransmitter such as tea phenol amine etc..The known PLP of research can promote transaminase to carry out transamination to improve internal DOPA at present
The content of amine, is the medicine for being clinically used to treat parkinsonism.Also studies have reported that, clinic gives PLP and can play
The treatment neonatal seizure encephalopathic of effect.Chinese patent literature CN200880018228.6, publication date 2010.03.31, is also disclosed
P5P can treat tardive dyskinesia, and the treatment is orally to give 100-4000mg/ days, such as 100-
750mg/ days or about 250mg/ days.And the research on PLP in tumour at present is seldom, correlative study is there is no in oophoroma.
And the new application for further researching and developing PLP would be beneficial for making full use of this kind of compound, promote controlling for clinically relevant disease
Treat.
The content of the invention
The purpose of the present invention is directed to deficiency of the prior art, there is provided a kind of new application of phosphopyridoxal pyridoxal phosphate.
In the first aspect of the present invention, there is provided application of the phosphopyridoxal pyridoxal phosphate in the medicine for preparing treatment oophoroma.
In the second aspect of the present invention, there is provided phosphopyridoxal pyridoxal phosphate is in the reagent for suppressing human epithelial ovarian carcinoma cells proliferation is prepared
Using.
Described ovarian cancer cell is SK-OV-3 or OVCAR-3.
The invention has the advantages that：
The present invention is experiments prove that PLP can suppress human epithelial ovarian carcinoma cells proliferation, therefore can be used to prepare treatment oophoroma
Medicine, or preparation research ovary carcinogenesis development mechanism related reagent.Additionally, in the research process of present inventor
It was found that, PLP makees compared to other materials for the inhibitory action of human epithelial ovarian carcinoma cells proliferation for the suppression of human epithelial ovarian carcinoma cells proliferation
With will significantly much.
PLP known in the state of the art is the activity form of vitamin B6, and vitamin B6 is water soluble vitamin, even if greatly
Dose application is also comparatively safe without toxicity, therefore PLP has very strong clinical practice possible in terms of oophoroma is treated.
Brief description of the drawings
Fig. 1 .PLP suppress the experimental result of human epithelial ovarian carcinoma cells proliferation.A：SK-OV-3；B：OVCAR-3.Three times independent real
Test.* P is shown<0.05.
Specific embodiment
The specific embodiment that the present invention is provided is elaborated below in conjunction with the accompanying drawings.
Embodiment 1
1st, PLP is purchased from sigma companies, and by specification requirement is configured to the mother liquor that concentration is 50mg/ml with 1M HCl.
2nd, PLP can suppress the propagation of ovarian cancer cell
SK-OV-3 (3000 cells/wells) and OVCAR-3 (5000 cells/wells) spreads 96 orifice plates, is given after 24 hours
PLP (0.5mg/ml) intervenes, and control group (HCl groups) uses equivalent HCl.WST methods detection propagation efficiency, surveys 24 small with ELIASA respectively
When, 48 hours, the absorbance of 72 hours OD450nm.Before each time point detection, original culture medium, plus fresh serum free training are abandoned
Base is supported, and adds 10 μ l WST-1 per hole, put back to incubator and continue to cultivate 2 hours.Referring to Fig. 1, PLP is small 48 for WST experiment displays
When and can substantially suppress within 72 hours growth (the * P of Ovarian Cancer Cells SK-OV-3 and OVCAR-3<0.05).
Result above prompting PLP can be used to prepare the medicine for the treatment of oophoroma, or preparation research ovary carcinogenesis development machine
The related reagent of system.And find that PLP will be significantly better than for the inhibitory action of human epithelial ovarian carcinoma cells proliferation in inventor's research process
Some other compound.
The above is only the preferred embodiment of the present invention, it is noted that for the ordinary skill people of the art
Member, on the premise of the inventive method is not departed from, can also make some improvement and supplement, and these are improved and supplement also should be regarded as
Protection scope of the present invention.
Claims (3)
1. application of the phosphopyridoxal pyridoxal phosphate in the medicine for preparing treatment oophoroma.
2. application of the phosphopyridoxal pyridoxal phosphate in the reagent for suppressing human epithelial ovarian carcinoma cells proliferation is prepared.
3. application according to claim 2, it is characterised in that described ovarian cancer cell is SK-OV-3 or OVCAR-3.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201611096574.9A CN106727620B (en) | 2016-12-01 | 2016-12-01 | Application of pyridoxal phosphate in preparation of medicine for treating ovarian cancer |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201611096574.9A CN106727620B (en) | 2016-12-01 | 2016-12-01 | Application of pyridoxal phosphate in preparation of medicine for treating ovarian cancer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN106727620A true CN106727620A (en) | 2017-05-31 |
| CN106727620B CN106727620B (en) | 2020-03-31 |
Family
ID=58884608
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201611096574.9A Active CN106727620B (en) | 2016-12-01 | 2016-12-01 | Application of pyridoxal phosphate in preparation of medicine for treating ovarian cancer |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN106727620B (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112691103A (en) * | 2020-12-28 | 2021-04-23 | 重庆医科大学附属第一医院 | Application of pyridoxal in preparation of medicine for treating ovarian cancer |
| CN115531380A (en) * | 2022-09-19 | 2022-12-30 | 重庆医科大学附属第一医院 | Application of fluoropyridoxine in preparation of anti-cancer drugs |
-
2016
- 2016-12-01 CN CN201611096574.9A patent/CN106727620B/en active Active
Non-Patent Citations (3)
| Title |
|---|
| ANA MOLINA等: "Vitamin B6 suppresses growth and expression of albumin gene in a human hepatoma cell line HepG2", 《NUTRITION AND CANCER》 * |
| 孙正怡等: "DNA拓扑异构酶Ⅰ抑制剂在卵巢癌治疗中的应用", 《中华妇产科杂志》 * |
| 陈兴等: "磷酸吡哆醛对H22肝癌细胞DNA拓扑异构酶Ⅰ活性的影响", 《河北省科学院学报》 * |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112691103A (en) * | 2020-12-28 | 2021-04-23 | 重庆医科大学附属第一医院 | Application of pyridoxal in preparation of medicine for treating ovarian cancer |
| WO2022143010A1 (en) * | 2020-12-28 | 2022-07-07 | 重庆医科大学附属第一医院 | Use of pyridoxal in preparation of drugs for treating ovarian cancer |
| GB2611905A (en) * | 2020-12-28 | 2023-04-19 | First Affiliated Hospital Of Chongqing Medical Univ | Use of pyridoxal in preparation of drugs for treating ovarian cancer |
| CN115531380A (en) * | 2022-09-19 | 2022-12-30 | 重庆医科大学附属第一医院 | Application of fluoropyridoxine in preparation of anti-cancer drugs |
| WO2024060834A1 (en) * | 2022-09-19 | 2024-03-28 | 重庆医科大学附属第一医院 | Use of fluoropyridoxal in preparing medicament against cancer |
Also Published As
| Publication number | Publication date |
|---|---|
| CN106727620B (en) | 2020-03-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Babak et al. | Modulation of intracellular copper levels as the mechanism of action of anticancer copper complexes: Clinical relevance | |
| CN106727620A (en) | Application of the phosphopyridoxal pyridoxal phosphate in the medicine for preparing treatment oophoroma | |
| Hosein et al. | Pancreatic cancer metabolism: molecular mechanisms and clinical applications | |
| Wilsbacher et al. | Discovery and characterization of novel nonsubstrate and substrate NAMPT inhibitors | |
| CN107142241A (en) | A kind of nutrient solution and its cultural method for improving in-vitro maturity of porcine oocytes quality and developmental potentiality | |
| Zuzčák et al. | Cellular metabolism in pancreatic cancer as a tool for prognosis and treatment | |
| Qiu et al. | Effects of liver-targeted drugs on expression of immune-related proteins in hepatocellular carcinoma cells | |
| CN113768911B (en) | APOBEC3B inhibitor and application thereof | |
| GB2611905A (en) | Use of pyridoxal in preparation of drugs for treating ovarian cancer | |
| CN103834615A (en) | Serum-free medium suitable for culturing gamma delta T cells | |
| CN106377496A (en) | Anti-cancer transdermic absorption preparation | |
| TW201544108A (en) | Use of an isoquinoline alkaloid derivative in manufacturing a medication effective in AMPK activation | |
| CN104739838B (en) | Micromolecular inhibitor and the application on ornithine decarboxylase (ODC) is suppressed | |
| WO2019238143A3 (en) | Colorectal cancer solid tumour primary cell and colorectal cancer ascitic fluid primary tumour cell culturing method, and matching reagent | |
| CN107034176A (en) | A kind of nutrient solution and its cultural method for improving in vitro culture porcine oocytes developmental potentiality | |
| CN106727560A (en) | A kind of application of Comptothecin compounds as topoisomerase enzyme inhibitor in chronic hepatic diseases medicine is treated | |
| CN112438980A (en) | Application of mirtazapine and methotrexate combined medicine in preparation of liver cancer treatment medicine | |
| CN103751210B (en) | A kind of application of the extracting solution of natural variform arsenic | |
| CN102503892A (en) | Co-containing sandwich heteropolyacid as well as synthesis method and application thereof | |
| CN102061285A (en) | Application method for medicament based on NAD<+> and NADH | |
| CN104829569A (en) | Application of 2-phenyl-benzo-five-membered heterocycle compound and derivative of 2-phenyl-benzo-five-membered heterocycle compound | |
| CN104829568B (en) | A kind of 2 phenyl benzene a pair of horses going side by side five-membered heterocycles and its medical applications of derivant | |
| CN104212769A (en) | Cell culture medium additive used for highly producing monoclonal antibody | |
| WO2020097086A1 (en) | Combination therapy for cancer | |
| Li et al. | AAZ2 induces mitochondrial-dependent apoptosis by targeting PDK1 in gastric cancer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |